Viemed (VMD) COO Zehnder gets RSUs, phantom units and withholds shares

Rhea-AI Filing Summary

Viemed Healthcare, Inc. reported insider equity activity for Chief Operating Officer and director William Todd Zehnder. On January 19, 2026, he received 118,759 Restricted Stock Units (RSUs) and 29,690 phantom share units, each tied to one common share or its cash value and vesting in three equal annual installments beginning one year after the grant date.

On January 17, 2026, previously granted awards from January 17, 2023 partially vested. This led to the acquisition of 26,939 common shares from RSUs and 6,735 common shares tied to cash-settled phantom shares, followed by dispositions back to the company. The filing also shows 8,550 common shares withheld at $7.33 per share to cover taxes. After these transactions, Zehnder directly held 292,362 common shares, plus the new RSU and phantom unit balances.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ZEHNDER WILLIAM TODD

(Last) (First) (Middle)

625 E. KALISTE SALOOM RD.

(Street)

LAFAYETTE LA 70508

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VIEMED HEALTHCARE, INC. [ VMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	01/17/2026		M		26,939	A	(1)	300,912	D
Common Shares	01/17/2026		F		8,550(2)	D	$7.33(3)	292,362	D
Common Shares	01/17/2026		M		6,735	A	(4)	299,097	D
Common Shares	01/17/2026		D		6,735	D	$7.33(3)	292,362	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	01/17/2026		M			26,939	(5)	01/17/2026	Common Shares	26,939	$0	0	D
Phantom Share Units	(4)	01/17/2026		M			6,735	(6)	01/17/2026	Common Shares	6,735	(4)	0	D
Restricted Stock Units	(1)	01/19/2026		A		118,759		(7)	01/19/2029	Common Shares	118,759	$0	118,759	D
Phantom Share Units	(8)	01/19/2026		A		29,690		(9)	01/19/2029	Common Shares	29,690	$0	29,690	D

Explanation of Responses:

1. Each Restricted Stock Unit (RSU) represents a contingent right to receive one common share.

2. Shares that were withheld by the issuer to satisfy the reporting person's tax obligation resulting from the vesting of restricted stock units.

3. Per share value is based on the market closing price of the common shares for January 16, 2026.

4. Represents vesting of cash-settled phantom shares granted under the Issuer's Phantom Share Unit Plan. Each phantom share is the economic equivalent of one Company common share. The settlement of the phantom shares for cash is reported on this Form 4 as a disposition of the phantom shares being settled in exchange for the acquisition of the underlying Company common shares, and a simultaneous disposition of the underlying Company common shares to the Company for cash.

5. Restricted Stock Units (RSUs) granted to reporting person on January 17, 2023, which vest in three equal annual installments beginning on the first anniversary of the grant date.

6. Represents an award granted on January 17, 2023 under the Issuer's Phantom Share Unit Plan which vests in three equal annual installments beginning on the first anniversary of the grant date.

7. Restricted Stock Units (RSUs) granted to reporting person on January 19, 2026, which vest in three equal annual installments beginning on the first anniversary of the grant date.

8. Each phantom share represents a right to receive the cash value of one share of the Issuer's common shares which will be determined based on the Issuer's share price on the vesting date.

9. Represents an award granted on January 19, 2026 under the Issuer's Phantom Share Unit Plan which vests in three equal annual installments beginning on the first anniversary of the grant date.

Remarks:

	/s/ Jesse Bergeron, Attorney-in-Fact	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Viemed (VMD) report for William Todd Zehnder?

The filing shows that William Todd Zehnder, Viemed Healthcare's Chief Operating Officer and director, had RSUs and phantom share units vest on January 17, 2026 and received new grants of both award types on January 19, 2026, along with related common share acquisitions and tax share withholdings.

How many RSUs did the Viemed (VMD) COO receive in the latest grant?

On January 19, 2026, William Todd Zehnder received 118,759 Restricted Stock Units, each representing a contingent right to receive one common share and vesting in three equal annual installments beginning on the first anniversary of the grant date.

What are the details of the phantom share unit grant reported by Viemed (VMD)?

On January 19, 2026, Zehnder was granted 29,690 phantom share units under Viemed's Phantom Share Unit Plan. Each phantom share represents the right to receive the cash value of one common share, determined based on the share price on the vesting date, and vests in three equal annual installments starting one year after the grant.

How many Viemed (VMD) common shares did the COO acquire and dispose of on January 17, 2026?

On January 17, 2026, vesting of prior awards led to the acquisition of 26,939 common shares from RSUs and 6,735 common shares related to phantom shares. The filing also reports dispositions of 8,550 shares, withheld to cover taxes, and 6,735 shares back to the company in connection with cash settlement of phantom shares.

At what price were Viemed (VMD) shares withheld or disposed of for tax and settlement purposes?

The shares withheld to satisfy tax obligations and the common shares disposed of to the company in connection with phantom share settlement were priced at $7.33 per share, based on the market closing price of Viemed's common shares on January 16, 2026.

How many Viemed (VMD) common shares does the COO hold after these transactions?

After the reported transactions on January 17, 2026, William Todd Zehnder directly held 292,362 Viemed common shares, in addition to his outstanding RSU and phantom share unit awards.